Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Steinmeyer Law opens investigation into Aimmune Therapeutics, IncBy: Steinmeyer Law On August 6 Aimmune Therapeutics, Inc. (“Aimmune” IN THE REGISTRARION STATEMENT AND PROSPECUTS DR “Howard V. Raff, Ph.D., was not only described as the second employee but the COO serving as both key scientific and management as as he has ” served as our Chief Operating Officer since July 2012. From 2007 to March 2012, Dr. Raff served as Chief Operating Officer for APT Pharmaceuticals, Inc., a pharmaceutical company. Dr. Raff was Vice President of Development Management for Chiron Corporation, a biotechnology company, from 1995 until its acquisition by Novartis International AG, a pharmaceutical company, in 2006. Dr. Raff also served as the head of west coast operations for The Biologics Consulting Group, a regulatory consulting firm in product development and regulatory strategy for biologics, drugs and medical devices, and spent 11 years in discovery research and development for Bristol-Myers Squibb, a pharmaceutical company. Dr. Raff has been involved with the development and approval of several drugs in the U.S. and Europe, including CTLA4-lg, Proleukin, Menjugate vaccine and Cubicin. Dr. Raff received a B.S. in Zoology from the University of Illinois and an M.S. and Ph.D. in Immunology and Microbiology from Washington State University.” If you purchased securities of Aimmune Therapeutics, Inc. (AIMT) and wish to know your rights go to this page https://steinmeyerlaw.com/ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|